Emyria Expands drug candidate library with fourth batch of MDMA-inspired analogues
- Emyria (EMD) progresses its pre-clinical MDMA-inspired drug discovery program with the University of Western Australia (UWA)
- The company and UWA have created their fourth batch of 14 novel MDMA analogues, which have been characterised and sent for safety screening
- With this fourth batch, the company’s product library now comprises over 140 neurologically active compounds
- The company has shipped five priority compounds to PsychoGenics in the US for advanced preclinical screening
- Shares in the company closed grey at 21.5 cents
